A
Agios Pharmaceuticals
Biopharmaceutical company discovering and developing therapeutics for cancer metabolism
At a glance
- Status
- Listed
- Listing
- IPO 2013
Open roles
Agios Pharmaceuticals in the Cambridge ecosystem
The Agios Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Series A1 investor entered at this stage
Series B and later5 investors entered at this stage
- BSBristol-Myers Squibb
- UTUniversity of Toronto
- UPUniversity of Pennsylvania
- HUHarvard University
- CECelgene
Source: Dealroom Talent Intelligence.
Alumni founders
Former Agios Pharmaceuticals employees who went on to found companies, sorted by Dealroom signal score.
XTXaira TherapeuticsEst. 2023
Marc Tessier-LavigneUnited States
ELELucidata.ioEst. 2015
ATAuron TherapeuticsEst. 2018
Kate YenUnited States
David ScaddenUnited States
MTMythic TherapeuticsEst. 2017
Brian FiskeUnited StatesPatents
96 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Agios Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Agios: FDA extends mitapivat sickle cell disease review to February 2027
Agios halts sickle-cell development of tebapivat after Phase 2 fails to show differentiation




